NCT03070171View on ClinicalTrials.gov

Bioequivalence of Tablet Formulation of Dabigatran Etexilate Compared to Commercial Capsule Formulation Following Oral Administration in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

March 21, 2017

Primary Completion Date

June 16, 2017

Study Completion Date

June 20, 2017

Conditions
Healthy
Interventions
DRUG

dabigatran etexilate

single dose

Trial Locations (1)

130-0004

SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT03070171 - Bioequivalence of Tablet Formulation of Dabigatran Etexilate Compared to Commercial Capsule Formulation Following Oral Administration in Healthy Male Subjects | Biotech Hunter | Biotech Hunter